Pegfilgrastim
Also known as: Fylnetra, Neulasta, PD‑L1, PEG-filgrastim, pegfilgrastim, SD/01, Udenyca, Ziextenzo
Source Pegfilgrastim at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Pegfilgrastim is a long‑acting, pegylated recombinant form of filgrastim used as a supportive therapy to reduce the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
Mechanism of Action
Binds to the G‑CSF receptor on hematopoietic cells, stimulating proliferation and differentiation of neutrophil precursors and enhancing neutrophil function
Routes of Administration
Goals & Uses
- Prevention of chemotherapy‑induced febrile neutropeniaSupportive OncologyHigh
- Reduction of chemotherapy dose delaysOncologic Supportive CareHigh
- Prevention of febrile neutropeniaInfection PreventionHigh
- Peripheral blood stem cell mobilizationHematology / TransplantationModerate
- Radiation injury mitigation (hematopoietic subsyndrome of acute radiation syndrome)Radiation Emergency MedicineModerate
Contraindications
- Hypersensitivity to filgrastim, pegfilgrastim, or PEGAllergy/ImmunologicHigh
- Patients with active myeloid malignancies (e.g., chronic myeloid leukemia)HematologicModerate
- Known hypersensitivity to pegfilgrastim, filgrastim, or any PEG componentAllergyHigh
- Administration within 14 days before and 24 hours after cytotoxic chemotherapyTiming/Drug InteractionHigh
Adverse Effects
- Sickle cell crisisHematologicRare
- Acute respiratory distress syndrome (ARDS)PulmonaryRare
- Bone painMusculoskeletalCommon
- Injection site reactionsLocalCommon
- Splenic ruptureGastrointestinal/HematologicRare
- AortitisCardiovascularRare
- Bone pain / musculoskeletal painMusculoskeletalCommon
Drug Interactions
- Cytotoxic chemotherapy agentsHigh
- Concurrent chemotherapy agentsLow
- LithiumLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Patients with latex allergyAllergyRelative
- Pediatric patients < 45 kg receiving fixed 6 mg dosePediatricRelative
- Pregnant or lactating womenReproductiveRelative
- Patients with sickle cell diseaseHematologic DisorderRelative
- Pediatric patients (<2 years)AgeRelative
Regulatory Status
- European UnionApprovedApproved: Reduction of duration of severe neutropenia in adult cancer patients undergoing chemotherapyEMA approval aligns with US indications.
- United StatesApprovedApproved: Prevention of febrile neutropenia in adult patients receiving myelosuppressive chemotherapyFDA label includes adult and select pediatric use.
- United KingdomApprovedApproved: Supportive treatment to reduce chemotherapy‑induced neutropeniaMHRA follows EU marketing authorization.
Approved by the US FDA (2002) and EMA (2003) for chemotherapy‑induced neutropenia; marketed under the brand name Neulasta.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Pegfilgrastim?
Pegfilgrastim is a long‑acting, pegylated recombinant form of filgrastim used as a supportive therapy to reduce the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
What is Pegfilgrastim used for?
Pegfilgrastim is educationally associated with: Prevention of chemotherapy‑induced febrile neutropenia, Reduction of chemotherapy dose delays, Prevention of febrile neutropenia, Peripheral blood stem cell mobilization, Radiation injury mitigation (hematopoietic subsyndrome of acute radiation syndrome). Educational only — not medical advice.
How is Pegfilgrastim administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Pegfilgrastim?
Reported adverse effects include: Sickle cell crisis, Acute respiratory distress syndrome (ARDS), Bone pain, Injection site reactions, Splenic rupture, Aortitis, Bone pain / musculoskeletal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Pegfilgrastim?
Recorded contraindications: Hypersensitivity to filgrastim, pegfilgrastim, or PEG, Patients with active myeloid malignancies (e.g., chronic myeloid leukemia), Known hypersensitivity to pegfilgrastim, filgrastim, or any PEG component, Administration within 14 days before and 24 hours after cytotoxic chemotherapy. Consult a qualified clinician before use.